1. Home
  2. Companies
  3. NUZ
  4. Material Events

Neurizon Therapeutics (ASX:NUZ) — Material Events

ASX:NUZ · 24 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 17 articles Notable 5 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
17
NIH grant opens expanded access pathway for Neurizon’s NUZ-001 ALS therapyHigh
NIH funds expanded access program for Neurizon's NUZ-001 ALS therapy
9 Sept 2026 ·Clinical Development Update - NIH Grant and Expanded Access Program ·Unexpected ·88
FDA Opens Potential Single-Trial Approval Pathway for Neurizon’s NUZ-001High
FDA says HEALEY ALS trial could support NUZ-001 approval pathway
6 Oct 2026 ·Regulatory and Clinical Trial Update ·Unexpected ·86
Neurizon Raises A$24.2m to Propel ALS Drug NUZ-001 into Pivotal TrialHigh
Neurizon launches A$24.2m equity raise to fund ALS trial and commercialisation of NUZ-001
23 Dec 2025 ·Equity Raising Presentation ·85
Neurizon Therapeutics Advances ALS Trial and Strengthens Financial Position in FY2026High
Neurizon Therapeutics reports FY2026 results, completes HEALEY ALS trial enrolment, and advances NUZ-001 clinical development
25 Aug 2026 ·Annual Report and Financial Results ·85
Neurizon Launches Pivotal Phase 2/3 Trial of NUZ-001 in ALS PatientsMedium
Neurizon Begins Phase 2/3 Dosing of NUZ-001 in HEALEY ALS Platform Trial
26 Feb 2026 ·Clinical Trial Update ·85
Neurizon Secures $44M to Propel NUZ-001 in Pivotal ALS TrialHigh
Neurizon secures $44.2M funding package to advance NUZ-001 in HEALEY ALS Platform Trial
23 Dec 2025 ·Capital Raising ·85
Neurizon Accelerates ALS Trial Results After Fastest Ever HEALEY EnrolmentMedium
Neurizon completes fastest enrolment in HEALEY ALS trial, accelerates topline results to Q2 2027
17 July 2026 ·Clinical Trial Update ·Unexpected ·85
Neurizon Clears FDA Hold, Raises $5.2M, Advances ALS Drug NUZ-001Medium
Neurizon clears FDA clinical hold, raises $5.2M, advances NUZ-001 into HEALEY ALS trial
31 Oct 2025 ·Shareholder Update Webinar Announcement ·85
Neurizon Advances ALS Drug with Key GMP Manufacturing MilestoneMedium
Neurizon completes GMP batches of NUZ-001, advancing FDA submission and ALS trial enrollment
4 Dec 2025 ·Regulatory Update ·85
FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Platform Trial EntryMedium
Neurizon's NUZ-001 Cleared by FDA for HEALEY ALS Platform Trial Entry
11 Dec 2025 ·Regulatory Update ·85
Neurizon Locks in Five-Year Supply Deal with Elanco to Boost NUZ-001 CommercialisationMedium
Neurizon secures five-year supply agreement with Elanco to advance NUZ-001 commercialisation
17 June 2026 ·Supply Agreement Announcement ·80
Neurizon Expands HEALEY ALS Trial Cohort to 240 Participants with Accelerated Timeline and Stable CostsMedium
Neurizon expands HEALEY ALS trial cohort to 240 participants with accelerated timeline and stable costs
27 May 2026 ·Clinical Trial Update ·80
Neurizon Passes Halfway Mark in Expanded HEALEY ALS Trial Ahead of ScheduleMedium
Neurizon surpasses 50% dosing milestone in HEALEY ALS Platform Trial ahead of schedule
12 June 2026 ·Clinical Trial Progress Update ·75
Neurizon Advances ALS Drug Trial Despite FDA Fast Track SetbackMedium
Neurizon's ALS Drug NUZ-001 Advances in Clinical Trial; FDA Denies Fast Track Designation Pending More Data
2 Jan 2026 ·Regulatory and Development Update ·75
Neurizon Secures $5.88M to Propel ALS Drug Trial ForwardMedium
Neurizon raises $5.88M via entitlement offer to fund ALS trial progress
27 Jan 2026 ·Capital Raising ·75
Neurizon Raises A$2.7M to Close Entitlement Offer Shortfall, Boosting NUZ-001 DevelopmentMedium
Neurizon raises A$2.7M via placement of entitlement offer shortfall to support NUZ-001 development
16 Apr 2026 ·Capital Raising ·75
Neurizon Names Global Pharma Executive Chris Bremer as CEO Ahead of ALS ResultsMedium
Neurizon appoints Dr Chris Bremer as CEO to lead late-stage ALS drug development
7 Sept 2026 ·Executive Appointment ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.